Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s stock price shot up 3.1% on Monday . The stock traded as high as $12.41 and last traded at $12.40. 14,687 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 168,356 shares. The stock had previously closed at $12.03.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on ALMS shares. Leerink Partners assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set an "outperform" rating and a $29.00 price objective on the stock. Leerink Partnrs raised shares of Alumis to a "strong-buy" rating in a research report on Tuesday, July 23rd. Morgan Stanley began coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set an "overweight" rating and a $36.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Monday, August 19th. Finally, Guggenheim started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set a "buy" rating and a $32.00 price target for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Alumis presently has an average rating of "Buy" and a consensus price target of $28.00.
Get Our Latest Stock Analysis on Alumis
Alumis Trading Up 4.6 %
The stock has a 50 day moving average price of $11.65.
Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.57) by ($21.53). On average, analysts predict that Alumis Inc. will post -6.86 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alumis
A number of institutional investors have recently modified their holdings of ALMS. SR One Capital Management LP purchased a new position in Alumis during the 2nd quarter valued at about $26,067,000. Yu Fan purchased a new position in shares of Alumis in the second quarter valued at approximately $10,502,000. Ally Bridge Group NY LLC acquired a new position in shares of Alumis in the second quarter valued at approximately $8,229,000. Towerview LLC purchased a new stake in Alumis during the 2nd quarter worth approximately $4,123,000. Finally, Millennium Management LLC acquired a new stake in Alumis during the 2nd quarter worth approximately $3,376,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Further Reading
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
